{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:11:45Z","timestamp":1773274305443,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/cgt.2016.22","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T10:21:33Z","timestamp":1464344493000},"page":"229-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy"],"prefix":"10.1038","volume":"23","author":[{"given":"S L","family":"Hulin-Curtis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Uusi-Kerttula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J D","family":"Chester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"BFcgt201622_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK . Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61: 183\u2013203.","journal-title":"CA Cancer J Clin"},{"key":"BFcgt201622_CR2","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","volume":"6","author":"C Larson","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 2015; 6: 19976\u201319989.","journal-title":"Oncotarget"},{"key":"BFcgt201622_CR3","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","volume":"108","author":"AL Parker","year":"2006","unstructured":"Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006; 108: 2554\u20132561.","journal-title":"Blood"},{"key":"BFcgt201622_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397\u2013409.","journal-title":"Cell"},{"key":"BFcgt201622_CR5","doi-asserted-by":"crossref","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins alpha vbeta and alpha vbeta promote adenovirus internalization but not virus attachment. Cell 73: 309\u2013319.","DOI":"10.1016\/0092-8674(93)90231-E"},{"key":"BFcgt201622_CR6","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/JVI.02696-06","volume":"81","author":"P Abbink","year":"2007","unstructured":"Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654\u20134663.","journal-title":"J Virol"},{"key":"BFcgt201622_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1128\/JVI.01878-08","volume":"83","author":"AL Parker","year":"2009","unstructured":"Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N et al. Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. J Virol 2009; 83: 479\u2013483.","journal-title":"J Virol"},{"key":"BFcgt201622_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320\u20131323.","journal-title":"Science"},{"key":"BFcgt201622_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/sj.cgt.7700284","volume":"8","author":"Z You","year":"2001","unstructured":"You Z, Fischer DC, Tong X, Hasenburg A, Aguilar-Cordova E, Kieback DG . Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther 2001; 8: 168\u2013175.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201622_CR10","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/S0959-8049(02)00131-4","volume":"38","author":"M Kim","year":"2002","unstructured":"Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38: 1917\u20131926.","journal-title":"Eur J Cancer"},{"key":"BFcgt201622_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1006\/gyno.2002.6607","volume":"85","author":"JS Kim","year":"2002","unstructured":"Kim JS, Lee SH, Cho YS, Choi JJ, Kim YH, Lee JH . Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR). Gynecol Oncol 2002; 85: 260\u2013265.","journal-title":"Gynecol Oncol"},{"key":"BFcgt201622_CR12","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3390\/v2102290","volume":"2","author":"L Coughlan","year":"2010","unstructured":"Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010; 2: 2290\u20132355.","journal-title":"Viruses"},{"key":"BFcgt201622_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v7112923","volume":"7","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, Hulin-Curtis SL, Davies J, Parker AL . Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 2015; 7: 1\u201334.","journal-title":"Viruses"},{"key":"BFcgt201622_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1017\/S0022172400070650","volume":"89","author":"E D'Ambrosio","year":"1982","unstructured":"D'Ambrosio E, Del Gross N, Chicca A, Midulla M . Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hygiene 1982; 89: 155\u2013161.","journal-title":"J Hygiene"},{"key":"BFcgt201622_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1089\/hum.2015.015","volume":"26","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, Legut A, Davies J, Jones R, Hudson E, Hanna L et al. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies. Hum Gene Ther 2015; 26: 320\u2013329.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201622_CR16","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels R, Zuijdgeest D, can Rijnsoever R, Hartkoorn E, Damen I, de B\u00e9thune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263\u20138271.","journal-title":"J Virol"},{"key":"BFcgt201622_CR17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","volume":"11","author":"E Nwanegbo","year":"2004","unstructured":"Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351\u2013357.","journal-title":"Clin Diagn Lab Immunol"},{"key":"BFcgt201622_CR18","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1128\/JCM.39.11.4187-4189.2001","volume":"39","author":"W Saitoh-Inagawa","year":"2001","unstructured":"Saitoh-Inagawa W, Tanaka K, Uchio E, Itoh N, Ohno S, Aoki K . Genome typing of adenovirus type 34 isolated in two cases of conjunctivitis in Sapporo, Japan. J Clin Microbiol 2001; 39: 4187\u20134189.","journal-title":"J Clin Microbiol"},{"key":"BFcgt201622_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","volume":"9","author":"AD Gaggar","year":"2003","unstructured":"Gaggar AD, Shayakhmetov MK, Lieber A . CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408\u20131412.","journal-title":"Nat Med"},{"key":"BFcgt201622_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1699-0463.1998.tb00233.x","volume":"106","author":"L Thorsteinsson","year":"1998","unstructured":"Thorsteinsson L, O\u2019Dowd I, Harrington M, Johnson M . The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 1998; 106: 869\u2013478.","journal-title":"APMIS"},{"key":"BFcgt201622_CR21","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1128\/JVI.69.5.2850-2857.1995","volume":"69","author":"SC Stevenson","year":"1995","unstructured":"Stevenson SC, Rollence M, White B, Weaver L, McClelland A . Human adenovirus serotypes 3 and 5 bind two different cellular receptors via the fibre head domain. J Virol 1995; 69: 2850\u20132857.","journal-title":"J Virol"},{"key":"BFcgt201622_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1248\/bpb.31.1819","volume":"10","author":"F Sakurai","year":"2008","unstructured":"Sakurai F . Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. Biol Pharm Bull 2008; 10: 1819\u20131825.","journal-title":"Biol Pharm Bull"},{"key":"BFcgt201622_CR23","first-page":"423","volume":"8","author":"D Stone","year":"2006","unstructured":"Stone D, Lieber A . New serotypes of adenoviral vectors. Curr Opin Mol Ther 2006; 8: 423\u2013431.","journal-title":"Curr Opin Mol Ther"},{"key":"BFcgt201622_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrg2141","volume":"8","author":"R Waehler","year":"2007","unstructured":"Waehler R, Russell SJ, Curiel DT . Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573\u2013587.","journal-title":"Nat Rev Genet"},{"key":"BFcgt201622_CR25","doi-asserted-by":"publisher","first-page":"10567","DOI":"10.1128\/JVI.01308-08","volume":"82","author":"H Wang","year":"2008","unstructured":"Wang H, Liu Y, Yi LiZ, Tuve S, Stone D, Kalyushniy O et al. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol 2008; 82: 10567\u201310579.","journal-title":"J Virol"},{"key":"BFcgt201622_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2144\/000112993","volume":"45","author":"RJ Stanton","year":"2008","unstructured":"Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GWG . Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 2008; 45: 659\u2013668.","journal-title":"Biotechniques"},{"key":"BFcgt201622_CR27","first-page":"2656","volume":"116","author":"R Alba","year":"2010","unstructured":"Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Gene Therapy 2010; 116: 2656\u20132664.","journal-title":"Gene Therapy"},{"key":"BFcgt201622_CR28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/10430340260185139","volume":"13","author":"A Hemminki","year":"2004","unstructured":"Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT . Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2004; 13: 1505\u20131514.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201622_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ymthe.2003.12.008","volume":"9","author":"P Sova","year":"2004","unstructured":"Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496\u2013509.","journal-title":"Mol Ther"},{"key":"BFcgt201622_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.virol.2009.08.038","volume":"394","author":"EV Shashkova","year":"2009","unstructured":"Shashkova EV, May SM, Barry MA . Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 2009; 394: 311\u2013320.","journal-title":"Virology"},{"key":"BFcgt201622_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.molonc.2014.12.007","volume":"9","author":"CK Ingemarsdotter","year":"2015","unstructured":"Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C et al. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol 2015; 9: 791\u2013805.","journal-title":"Mol Oncol"},{"key":"BFcgt201622_CR32","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/mt.2009.152","volume":"17","author":"JA Greig","year":"2009","unstructured":"Greig JA, Buckley SMK, Waddington SN, Parker AL, Bhella D, Pink R et al. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5\/Ad35 vectors. Mol Ther 2009; 17: 1683\u20131691.","journal-title":"Mol Ther"},{"key":"BFcgt201622_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0018205","volume":"6","author":"S Corjon","year":"2011","unstructured":"Corjon S, Gonazalez G, Henning P, Grichine A, Lindholm L, Boulanger P et al. Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon;heparan sulfate interaction. PLos One 2011; 6: 1\u201318.","journal-title":"PLos One"},{"key":"BFcgt201622_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1126\/science.1226625","volume":"338","author":"K Doronin","year":"2012","unstructured":"Doronin K, Flatt J, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M et al. Coagulation factor X activate innate immunity to human species C adenovirus. Science 2012; 338: 795\u2013798.","journal-title":"Science"},{"key":"BFcgt201622_CR35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.3107","volume":"19","author":"Z Xu","year":"2013","unstructured":"Xu Z, Qui Q, Tian J, Smith JS, Conenello G, Morita T et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013; 19: 452\u2013459.","journal-title":"Nat Med"},{"key":"BFcgt201622_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1749-8090-8-183","volume":"8","author":"KM White","year":"2013","unstructured":"White KM, Alba R, Parker AL, Wright AF, Bradshaw AC, Delles C et al. Assessment of a novel, capsid-modified adenovirus with an improves vascular gene transfer profile. J Cardiothorac Surg 2013; 8: 183\u2013189.","journal-title":"J Cardiothorac Surg"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cgt201622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cgt201622","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cgt201622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:14:09Z","timestamp":1684415649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFcgt201622"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2016.22","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]},"assertion":[{"value":"25 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}